4/28/2018
`
`Genentech: Press Releases
`
`Monday, Dec 9, 1996
`
`IDEC Pharmaceuticals and Genentech Announce Positive Final Results
`
`Results Of Phase II Combination Trial Also Reported
`
`Orlando -- December 9, 1996 --
`
`IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) and Genentech, Inc. (NYSE: GNE) have
`
`announced positive final results from a pivotal Phase III trial of IDEC-C2B8 as a single agent
`
`therapy for relapsed low grade or follicular non-Hodgkin‘s lymphoma. The trial, conducted in a
`
`total of 166 patients, confirmed the antibody's overall response rate and safety profile as seen in
`
`an earlier Phase II study. The companies additionally reported final results from a Phase II
`
`combination trial of IDEC- C2B8 and CHOP chemotherapy. Results of both trials are being
`
`presented today by clinical investigators Myron Czuczman, MD. of the Roswell Park Cancer
`
`Institute and Peter McLaughlin, MD. of the MD. Anderson Cancer Center at the annual meeting
`
`of the American Society of Hematology (ASH) held in this city.
`
`In Phase III open label, single arm testing of IDEC-C2B8 as a single agent therapeutic, each of the
`
`patients participating at over 30 trial centers received four infusions of the antibody on an
`
`outpatient basis during a 22-day period. Of 151 evaluable patients, 76 responded to treatment
`
`with IDEC-C2B8, for an overall response rate of 50%. Nine of these responses were complete
`
`responses (6%) and 67 were partial responses (44%). At over nine months' median followup, the
`
`median time to disease progression for responders following treatment with IDEC-C2B8 has not
`
`yet been reached. Of the responding patients, 70% remain in remission. Patients continue to be
`
`followed.
`
`The adverse events associated with IDEC-C2B8 were mostly infusion-related. These side effects
`
`consist primarily of mild to moderate flu-like symptoms (e.g., fevers, chills) and occur with
`
`greatest frequency upon initial administration. The symptoms are limited in duration to the
`
`period of infusion, may be ameliorated with oral acetaminophen and diphenhydramine and
`
`decrease significantly in frequency with subsequent infusions.
`
`As a matter of scientific interest, patients were also monitored for the presence of a tumor marker
`
`gene known in medical research as Bcl-2. Results presented at ASH revealed that the tumor
`
`httpszllww.gene.oom/media/press—releasesl4800/1996-12-09fidec-phannaceuticals-and-genentech—annou
`
`1/4
`
`1 of4
`
`Celltrion, Inc. 1103
`Celltrion v. Genentech
`|PR2017-01122
`
`
`
`1 of 4
`
`Celltrion, Inc. 1103
`Celltrion v. Genentech
`IPR2017-01122
`
`

`

`4/28/2018
`
`Genentech: Press Releases
`
`marker gene reverted to negative in the peripheral blood of over 70% of the patients who were
`
`positive at baseline, and in the bone marrow of over 50% of patients who were positive at
`
`baseline. Researchers have previously reported clearance of this marker from bone marrow with
`
`marrow transplantation regimens incorporating 'ex vivo' marrow purging and only rarely with
`
`chemotherapy regimens. However, the clinical significance of Bcl-2 conversion has not yet been
`
`determined.
`
`"IDEC-C2B8 has completed all Phase III clinical testing in support of regulatory filing and we are
`
`very gratified by the results we have seen for this agent to date," said Antonio J. Grille-Lopez,
`
`M.D., IDEC's senior vice president of medical and regulatory affairs. "We have confirmed IDEC-
`
`C2B8's potential as an effective, alternative therapy with limited toxicity for patients with B-cell
`
`lymphoma. Based on these results, we expect to file 3 Biological License Application for IDEC-
`
`C2B8 as a single agent therapy for relapsed patients with low grade or follicular non-Hodgkin's
`
`lymphoma in the first half of 1997."
`
`IDEC and Genentech are also investigating the use of IDEC-C2B8 in combination with other
`
`therapies for lymphoma and reported positive results in a Phase 11 open label, single arm trial
`
`combining IDEC-C2B8 with CHOP chemotherapy (a standard regimen of cyclophosphamide,
`
`doxorubicin, vincristine and prednisone). In this trial, patients with low grade or follicular
`
`lymphoma received six doses of IDEC-C2B8 over 21 weeks. Within this same time period, they
`
`also received six cycles of CHOP chemotherapy. Of the 35 patients completing all treatments, 35
`
`responded to treatment, for an overall response rate of 100%. Twenty-two patients (63%)
`
`achieved a complete response and 13 (3%) achieved a partial response. Patients tolerated the
`
`combination of IDEC-€2B8 and CHOP well; adverse events did not exceed those routinely
`
`observed with CHOP alone or those associated with IDEC-C2B8 alone, indicating compatibility of
`
`the two therapies.
`
`"Based on the limited toxicity and patient response rates observed to date for IDEC-C2B8 as a
`
`single agent therapeutic, Genentech and IDEC are committed to exploring further uses for IDEC-
`
`C2B8, both as a frontline therapy, and in combination with other anti-cancer treatments," said
`
`Sue Hellmann, M.D., Genentech vice president, medical affairs. "Genentech is currently
`
`conducting a study of IDEC-C2B8 in combination with chemotherapy in patients with
`
`intermediate grade disease and additional combination therapy trials are planned."
`
`https:llwww.gene.oom/medla/press—releasesl4800/1996-12-09/idec-phamiaoeuficaIs—and-genentech—annou
`
`2 of4
`
`214
`
`Celltrion, Inc. 1103
`Celltrion v. Genentech
`|PR2017-01122
`
`
`
`2 of 4
`
`Celltrion, Inc. 1103
`Celltrion v. Genentech
`IPR2017-01122
`
`

`

`4/28/2018
`
`Genentech: Press Releases
`
`B-cell lymphomas are malignancies of the body's antibody-producing immune system cells. Non-
`
`Hodgkin's lymphomas currently afflict roughly 225,000 Americans, with over 50,000 new
`
`diagnoses expected this year. Low grade and follicular lymphomas comprise about 65% of the
`
`total lymphoma. prevalence in the United States.
`
`IDEC-C2B8 is a monoclonal antibody that is therapeutically active on its own and does not
`
`require the attachment of radioisotopes or toxins to elicit its anti-tumor effect. The antibody
`
`targets a protein (the CD20 antigen) that is expressed on the surface of mature B cells and on B-
`
`cell tumors, but not on B-cell precursors or other body tissues. IDEC-C2B8 works by binding to
`
`its target antigen and recruiting the patient's natural defenses to attack and kill both malignant
`
`and normal mature B cells. In trials to date, the normal B cells regenerate from stem cells and
`
`return to normal levels within months following treatment with IDEC-C2B8. In addition, clinical
`
`results to date have shown that IDEC-C2B8 does not exhibit any significant toxicities that overlap
`
`with those produced by chemotherapy or high dose radiation. Thus, treatment with IDEC-C2B8
`
`has not precluded patients from receiving subsequent chemotherapeutic treatments. In addition,
`
`IDEC-C2B8 is administered over 22 days, versus the four- to eight-month course required for
`
`most conventional chemotherapies.
`
`IDEC and Genentech are developing IDEC-C2B8 in collaboration with F.Hoffmann-La Roche,
`
`Ltd. of Switzerland and Zenyaku Kogyo Co. Ltd. of Japan. Genentech, Inc. is a leading
`
`international biotechnology company that discovers, develops, manufactures and markets human
`
`pharmaceuticals for significant unmet medical needs. The company has headquarters in South
`
`San Francisco, California and is traded on the New York and Pacific Stock Exchanges under the
`
`symbol GNE.
`
`IDEC Pharmaceuticals focuses on developing targeted immunotherapies for the treatment of
`
`cancer and autoimmune diseases. IDEC's products are primarily designed to act through immune
`
`mechanisms and offer greater specificity of action, longer therapeutic effect and lower toxicity
`
`than is typical of existing therapies. All of IDEC's products are designed for administration in
`
`outpatient settings, providing the opportunity to reduce overall treatment costs.
`
`IDEC Pharmaceuticals' press releases and are available at no charge through PR Newswire's
`
`"Company News On Call" fax service. For a menu of IDEC's current press releases and quarterly
`
`reports or to retrieve a specific release, call (800) 758-5804, ext. 432581 or internet
`
`http://www.prnewswire.com.
`
`https:llwww.gene.oom/media/press—releasesl4800/1996-12-09/idec-pharmaceuticaIs—and-genentech—annou
`
`3 of4
`
`3l4
`
`Celltrion, Inc. 1103
`Celltrion v. Genentech
`|PR2017-01122
`
`
`
`3 of 4
`
`Celltrion, Inc. 1103
`Celltrion v. Genentech
`IPR2017-01122
`
`

`

`4/28/2018
`
`Genentech: Press Releases
`
`The statements made in this press release contain certain forward looking statements that involve
`
`a number of risks and uncertainties. Actual events or results may differ from the company's
`
`expectations. In addition to the matters described in this press release, timelines for clinical
`
`ongoing activity are subject to change, results of pending or future clinical trials cannot be
`
`accurately predicted and decisions by the FDA and other regulatory agencies, as well as the risk
`
`factors listed from time to time in the company's SEC filings, including but not limited to its
`
`Annual Reports on Form 10-K for the year ended December 31, 1995, and form S-3 filed May 3,
`
`1996, may affect the actual results achieved by the company.
`
`IDEC Pharmaceuticals is a registered U.S. trademark of the company. The company headquarters
`
`is located at 11011 Torreyana. Road, San Diego, CA 92121.
`
`CONTACT: Connie Matsui of IDPH, 619-550-8656; or Laura Leber of GNE, 415-225-5759.
`
`###
`
`https:llwww.gene.oom/media/press—releasesl4800/1996-12-09/idec-phannaoeuticaIs—and-genentech—annou
`
`4 of4
`
`4/4
`
`Celltrion, Inc. 1103
`Celltrion v. Genentech
`|PR2017-01122
`
`
`
`4 of 4
`
`Celltrion, Inc. 1103
`Celltrion v. Genentech
`IPR2017-01122
`
`